CD19 and neoplasm: Although objective clinical responses after CAR T treatment were observed and documented, adverse effects [e.g., cytokine release syndrome (CRS) and/or neurologic toxicity] and tumor relapse were reported (2, 9).The mechanism of CD19+ relapse is associated with poor T cell function and early CD19-CAR T cell disappearance (10).